Cardiogenic shock (CS) in a setting of aortic stenosis is associated with high mortality rates. In consequence, surgery is generally not a possibility for this patient group, and they usually undergo aortic valvuloplasty, resulting in a mortality rate of 33%-50% at 30 days, 70% at one year, and 90% at two years. While transcatheter aortic...
Below, we share March’s most read scientific abstracts in interventional cardiology at solaci.org. ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable...
Pulmonary vessels are densely innervated by sympathetic, parasympathetic, and sensitive fibers. According to the World Health Organization (WHO) pulmonary arterial hypertension (PAH) grade 1 consists of obliterating pulmonary vascular remodeling accompanied by a diminished generation of vessel dilators. Its pharmacological treatment has certain limitations and sympathetic pulmonary vascular denervation might be a valid treatment alternative,...
Left main coronary artery (LMCA) intervention with significant lesions on both coronary angiography and intravascular ultrasound (IVUS), either through angioplasty (PCI) or myocardial revascularization surgery (MRS), is directly related to a decrease in long-term adverse clinical events. However, the relationship between subclinical LMCA disease (preserved luminal diameters) and long-term mortality is still unknown. A retrospective...
Pulmonary hypertension is associated with higher mortality after both aortic valve replacement and transcatheter aortic valve replacement (TAVR). This is a dynamic phenomenon, and what happens after TAVR —during the periprocedure— and its impact are yet to be evaluated. Researchers conducted a subanalysis of the Japanese OCEAN TAVI Registry, which included 1872 patients who were divided...
✔️ MITRAL VALVE Session ✔️ SOLACI-SOCIME 2022 Scientific Session 👨🏫 Content: 00:09 – Welcoming Words – Dr. Jorge Cortés (MEX) 01:16 – TAVR for aortic regurgitation – Dr. Raj Makkar (USA) 18:53 – Reduced leaflet motion: the real clinical impact – Dr. Ole de Backer (DNK) 34:17 – TAVR in bicuspid aortic valve: Clinical evidence...
Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce...
This study was carried out to assess the safety and efficacy of the TriClip (edge-to-edge repair) in patients with severe tricuspid regurgitation with persistent symptoms despite medical treatment and high surgical risk. It is a prospective multicenter single arm study including 300 patients of mean age 78±7.6; 7.7% presented prior aortic intervention and 28% prior...
Infective Endocarditis (IE) rate after TAVR ranges from 0.7% to 3.4%, depending on the different analyses, and is comparable to that after SAVR. Close to 50% of patients treated with surgery received a prosthetic valve; in TAVR, the figure is lower, possibly due to the characteristics of patients (even though it remains unclear). Researchers looked...
We recently published the success of balloon-expandable Sapien valve when used as mitral valve replacement. We now hear about its success as pulmonary valve replacement. Previous experiences with this prosthesis for aortic valve replacement have encouraged many operators to attempt fixing other valves. At first, there were exceptional cases considered compassionate treatments. However, experience has...